Welcome to our dedicated page for Radnet news (Ticker: RDNT), a resource for investors and traders seeking the latest updates and insights on Radnet stock.
RadNet, Inc. (NASDAQ: RDNT) generates a steady flow of news as a national provider of freestanding, fixed-site diagnostic imaging services and as the parent of DeepHealth, its AI-powered health informatics division. News about RadNet often highlights developments across its network of 407 owned and/or operated outpatient imaging centers in markets such as Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas, as well as updates from its Digital Health segment.
Investors and observers following RDNT news will encounter announcements on topics such as acquisitions of imaging centers, expansion into new regional markets and updates on RadNet’s operational performance. For example, the company has reported acquisitions like Radiology Regional in Southwest Florida, adding multiple imaging centers and staff to its Florida footprint. Earnings releases and financial guidance updates are also frequent news items, reflecting trends in imaging volumes, segment revenue and Adjusted EBITDA for both the Imaging Center and Digital Health segments.
RadNet’s DeepHealth division is another major source of news, with press releases covering the launch of AI-powered clinical suites, imaging informatics platforms and collaborations with partners. Recent communications have described products such as Breast Suite, Thyroid Suite, Operations Suite, Diagnostic Suite and TechLive, as well as research findings published in scientific journals and showcased at industry conferences like RSNA. News may also cover strategic collaborations, including letters of intent and partnerships with companies such as GE HealthCare to expand AI-powered imaging solutions across modalities and geographies.
Because RadNet regularly issues updates on its financial results, acquisitions, digital health initiatives and research milestones, the RDNT news page can be a useful resource for tracking how the company’s imaging center operations and DeepHealth portfolio evolve over time. Readers interested in diagnostic imaging services, AI in radiology and healthcare operations technology may find RadNet’s news particularly relevant.
RadNet, Inc. (NASDAQ: RDNT) announced a partnership between its AI subsidiary Aidence and Google Health to license AI technology for lung nodule malignancy prediction. This collaboration aims to enhance early lung cancer diagnosis and minimize unnecessary procedures. Lung cancer screenings with low-dose CT significantly reduce mortality rates. Aidence's deep learning model will be developed and validated with Google Health's expertise, although no regulatory applications or sales orders have been initiated yet. The partnership focuses on improving clinical workflows and deployment of AI in diagnostics.
RadNet, Inc. (NASDAQ: RDNT) will have its Executive Vice President and Chief Financial Officer, Mark Stolper, present at the BofA Securities 2022 Leveraged Finance Conference on November 29, 2022, at 11:50 a.m. PT. The presentation will take place in Boca Raton, FL. Interested parties can access live and archived webcasts through BofA's website and RadNet's official site under the “About RadNet” section.
RadNet, NASDAQ: RDNT, reported a 5.2% revenue increase to $350 million in Q3 2022, driven by its Imaging Centers segment, which grew 5.1% to $349.1 million. However, Adjusted EBITDA fell 8.5% to $50.2 million, primarily due to rising costs and labor shortages. Net Income dropped to $668,000 with diluted earnings per share at $0.01. The company revised its full-year guidance downward, citing ongoing cost challenges. Future growth strategies include operational expansions and acquisitions to enhance service capacity.
RadNet, Inc. (NASDAQ: RDNT) has acquired a 75% interest in London-based Heart & Lung Imaging Limited, enhancing its capacity in lung cancer diagnostics. HLH operates a network of over 70 radiologists and is a leader in NHS England's Targeted Lung Health Check (TLHC) program, which aims to screen one million lung cancer patients by 2026. This acquisition leverages RadNet’s AI technology to improve diagnostic accuracy and reduce mortality rates in lung cancer. CEO Dr. Howard Berger emphasized the strategic importance of early detection in improving patient outcomes and reducing healthcare costs.
RadNet, Inc. (NASDAQ: RDNT) announced the hosting of a conference call on November 9, 2022, at 7:30 a.m. PT (10:30 a.m. ET) to discuss its third quarter 2022 financial results. Investors can join by calling 800-239-9838 (domestic) or 929-477-0448 (international). The call will also be available via archived webcast. RadNet, recognized as a leader in diagnostic imaging services, operates 353 outpatient imaging centers across multiple states and employs approximately 9,000 people.
RadNet, Inc. (NASDAQ: RDNT) announced its joint venture, New Jersey Imaging Network (NJIN), has acquired the outpatient radiology assets of Montclair Radiology, enhancing NJIN's presence in northern New Jersey. Montclair Radiology operates six imaging centers and serves a patient population of 16 million, performing over 200,000 procedures annually. The acquisition is expected to add over $40 million in annual revenue to NJIN, supporting RadNet's mission to provide high-quality, cost-effective imaging services, while also benefitting Montclair Radiology's established reputation in the community.
RadNet reported a 6.1% increase in revenue for Q2 2022, totaling $354.4 million, compared to $333.9 million in Q2 2021. Revenue from the Imaging Centers segment rose by 5.7% to $352.8 million. Adjusted EBITDA, excluding AI losses, was $55.5 million, a 3.2% decrease year-over-year. The company reaffirmed its 2022 guidance, maintaining revenue expectations between $1.36 billion to $1.41 billion. Despite inflation and Medicare reimbursement cuts, RadNet remains optimistic about future growth from new centers and joint ventures.
RadNet, Inc. (NASDAQ: RDNT) announced it will host a conference call on August 9, 2022, at 7:30 a.m. PT to discuss its second-quarter 2022 financial results. Investors can participate by calling 800-458-4148 or 929-477-0324 for international access. The event will also feature archived webcasts. RadNet is a leading provider of diagnostic imaging services in the U.S., operating 351 outpatient imaging centers, and employing approximately 9,000 personnel across multiple states.
RadNet, a leader in diagnostic imaging services, announced that Mark Stolper, CFO, will present at the Jefferies 2022 Global Healthcare Conference on June 8, 2022, at 9:00 a.m. ET. The event will take place in New York, NY, and will be accessible via live and archived webcasts. RadNet operates 351 outpatient imaging centers across multiple states, including California and New York, employing approximately 9,000 staff members. For more details on the presentation, visit RadNet's website.
RadNet, Inc. (NASDAQ: RDNT) announced FDA clearances for its AI-based diagnostic tools: DeepHealth Saige-DX™ mammography and Quantib® Prostate 2.0 MRI algorithms. Saige-DX enhances breast cancer detection, resulting in improved accuracy and reduced false positives among radiologists. Quantib Prostate 2.0 streamlines prostate MRI reporting with new automated features. The approvals align with RadNet's commitment to improving cancer care and patient outcomes, echoing the Biden administration's Cancer Moonshot initiative to reduce cancer mortality rates.
FAQ
What is the current stock price of Radnet (RDNT)?
What is the market cap of Radnet (RDNT)?
